Aspen expects a R2 billion profit from selling a drug it will go on manufacturing for a decade

Business BagelChristian Maidman · 5 November 2026 at 02:45

Aspen is selling the European rights to its Ovestin menopause treatment for €197 million while keeping the work of making it, and the gap between the price and the brand's book value produces the profit.

This story was written and published by Business Bagel. Business.co.za shows its headline and teaser from the publisher’s RSS feed and links to the original.